Published in Hum Pathol on August 01, 2006
Mitochondrial regulation of cancer associated nuclear DNA methylation. Biochem Biophys Res Commun (2007) 0.98
Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Res (2009) 0.97
Spontaneous transformation of murine epithelial cells requires the early acquisition of specific chromosomal aneuploidies and genomic imbalances. Genes Chromosomes Cancer (2011) 0.92
p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia (2008) 0.92
DNA methylation: its role in cancer development and therapy. Curr Probl Cancer (2008) 0.88
Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol (2009) 0.84
Aberrant DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report. J Med Case Rep (2011) 0.82
Important roles of multiple Sp1 binding sites and epigenetic modifications in the regulation of the methionine sulfoxide reductase B1 (MsrB1) promoter. BMC Mol Biol (2007) 0.82
Increased frequency of CpG island methylator phenotype and CDH1 methylation in a gastric cancer high-risk region of china. Transl Oncol (2008) 0.81
Promoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern India. Transl Oncol (2009) 0.77
Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer. Breast Cancer (Auckl) (2016) 0.77
O(6)-methylguanine-DNA methyltransferase as a prognostic and predictive marker for basal-like breast cancer treated with cyclophosphamide-based chemotherapy. Oncol Lett (2014) 0.76
5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. Cancer Lett (2014) 0.75
A Catalogue of Altered Salivary Proteins Secondary to Invasive Ductal Carcinoma: A Novel In Vivo Paradigm to Assess Breast Cancer Progression. Sci Rep (2016) 0.75
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst (2006) 7.29
Choosing the right cell line for breast cancer research. Breast Cancer Res (2011) 3.57
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23
Identification of microcephalin, a protein implicated in determining the size of the human brain. Am J Hum Genet (2002) 3.13
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
Breast cancer cell lines: friend or foe? Breast Cancer Res (2003) 1.98
Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res (2012) 1.97
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat (2009) 1.73
TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. Am J Hum Genet (2011) 1.65
Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer (2002) 1.65
Mutations in microcephalin cause aberrant regulation of chromosome condensation. Am J Hum Genet (2004) 1.62
Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res (2008) 1.58
The rising incidence of male breast cancer. Breast Cancer Res Treat (2008) 1.54
Breast carcinoma in women age 25 years or less. Cancer (2002) 1.50
Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol (2003) 1.43
Male breast carcinoma: increased awareness needed. Breast Cancer Res (2011) 1.40
Estrogen receptor regulation: don't forget translation. Breast Cancer Res Treat (2010) 1.39
Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.38
Human ASPM participates in spindle organisation, spindle orientation and cytokinesis. BMC Cell Biol (2010) 1.29
Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol (2012) 1.13
Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res (2010) 1.12
A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat (2011) 1.12
Surgery induced immunosuppression. Surgeon (2010) 1.09
Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res (2004) 1.07
MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J Pathol (2013) 1.07
Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol (2004) 1.06
Steroid hormone receptor expression in breast cancer stroma. Breast Cancer Res Treat (2014) 1.05
Intramammary lymph node metastasis predicts poorer survival in breast cancer patients. Surg Oncol (2009) 1.05
DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. J Surg Res (2008) 1.04
Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr) (2012) 1.00
The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. J Pathol (2002) 0.99
Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res (2008) 0.98
Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer (2011) 0.97
The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. J Clin Pathol (2012) 0.97
A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Res Treat (2007) 0.96
Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study. J Clin Pathol (2012) 0.96
Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J Cancer (2006) 0.95
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat (2010) 0.94
Patient-reported outcomes in breast oncology: a review of validated outcome instruments. Tumori (2012) 0.93
The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol (2012) 0.93
Differential regulation of oestrogen receptor β isoforms by 5' untranslated regions in cancer. J Cell Mol Med (2010) 0.92
A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat (2005) 0.92
The oligometastatic state in breast cancer: hypothesis or reality. Breast (2005) 0.91
Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet (2002) 0.91
MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol (2003) 0.91
Surgeon and breast unit volume-outcome relationships in breast cancer surgery and treatment. Ann Surg (2013) 0.90
Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. Biochim Biophys Acta (2013) 0.89
Expression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanisms. Biochem J (2010) 0.89
ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. Am J Pathol (2011) 0.88
Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS One (2013) 0.85
Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Res Treat (2014) 0.85
Culture, attitude and knowledge about breast cancer and preventive measures: a qualitative study of South Asian breast cancer patients in the UK. Asian Pac J Cancer Prev (2011) 0.85
Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol (2010) 0.84
Intracellular flow cytometric analysis of primary cultured breast tumor cells. Cancer Invest (2002) 0.84
Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol (2003) 0.83
The evolving role of oestrogen receptor beta in clinical breast cancer. Breast Cancer Res (2008) 0.83
CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol (2011) 0.83
Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Clin Cancer Res (2008) 0.83
Identification of stage-specific breast markers using quantitative proteomics. J Proteome Res (2013) 0.82
A high-throughput assay to identify modifiers of premature chromosome condensation. J Biomol Screen (2013) 0.82
Epithelial-mesenchymal interactions in breast cancer: evidence for a role of nuclear localized β-catenin in carcinoma-associated fibroblasts. Histopathology (2011) 0.82
Ogilvie's syndrome with caecal perforation after Caesarean section: a case report. J Med Case Rep (2009) 0.81
Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. J Pathol (2003) 0.80
Gene expression of ERbeta isoforms in laser microdissected human breast cancers: implications for gene expression analyses. Cell Oncol (2009) 0.80
Application of differential display, with in situ hybridization verification, to microscopic samples of breast cancer tissue. Int J Exp Pathol (2003) 0.79
Management of palpable but radiologically occult breast abnormalities. Acta Cytol (2012) 0.79
Conditions of the male breast: Gynaecomastia and male breast cancer (Review). Mol Med Rep (2011) 0.79
NuMA overexpression in epithelial ovarian cancer. PLoS One (2012) 0.79
Perioperative reductions in circulating lymphocyte levels predict wound complications after excisional breast cancer surgery. Ann Surg (2011) 0.79
External validation of the ImmunoRatio image analysis application for ERα determination in breast cancer. J Clin Pathol (2013) 0.79
Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer. Breast Cancer Res Treat (2014) 0.78
Clinical importance of estrogen receptor beta isoforms in breast cancer. J Clin Oncol (2008) 0.78